Literature DB >> 10589759

Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer.

C M Chan1, A E Lykkesfeldt, M G Parker, M Dowsett.   

Abstract

Regulation of gene transcription as a consequence of steroid receptor-DNA interaction is mediated via nuclear receptor interacting proteins (RIPs), including coactivator or corepressor proteins, which interact with both the receptor and components of the basic transcriptional unit and vary between cell types. The aim of this study was to test the hypothesis that resistance of some breast carcinomas to tamoxifen was associated with inappropriate expression of some of these RIPs. Using Northern analysis, we observed no significant difference between the amount of either TIF-1 or SUG-1 mRNA expressed in parental MCF-7 and MCF-7 tamoxifen-resistant cell lines. However, the expression of RIP140 mRNA was lower in the resistant cell line and in the presence of estradiol, the level of RIP140 mRNA was higher in the resistant cells but not in the parental cells. In a cohort of 19 tamoxifen-resistant breast tumor samples, there was no significant difference in the level of the RIP140 and TIF-1 and corepressor SMRT mRNA compared with tamoxifen-treated tumors (n = 6) or untreated tumors (n = 21). However, SUG-1 mRNA was lower in resistant breast tumors. These data provide no support for increased expression of these RIPs or decreased expression of corepressor SMRT for being a mechanism for resistance of breast tumors to tamoxifen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589759

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.

Authors:  Sandipan Chakraborty; Pradip Kumar Biswas
Journal:  J Mol Model       Date:  2014-07-25       Impact factor: 1.810

Review 2.  Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.

Authors:  Stéphanie Légaré; Mark Basik
Journal:  Mol Endocrinol       Date:  2016-07-20

3.  Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor.

Authors:  Sudipan Karmakar; Tong Gao; Margaret C Pace; Steffi Oesterreich; Carolyn L Smith
Journal:  Mol Endocrinol       Date:  2010-04-14

4.  Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence.

Authors:  Carolyn L Smith; Ilenia Migliaccio; Vaishali Chaubal; Meng-Fen Wu; Margaret C Pace; Ryan Hartmaier; Shiming Jiang; Dean P Edwards; M Carolina Gutiérrez; Susan G Hilsenbeck; Steffi Oesterreich
Journal:  Breast Cancer Res Treat       Date:  2012-09-27       Impact factor: 4.872

5.  RIP140 gene and protein expression levels are downregulated in visceral adipose tissue in human morbid obesity.

Authors:  Victoria Catalán; Javier Gómez-Ambrosi; Amaia Lizanzu; Amaia Rodríguez; Camilo Silva; Fernando Rotellar; María J Gil; Javier A Cienfuegos; Javier Salvador; Gema Frühbeck
Journal:  Obes Surg       Date:  2009-04-15       Impact factor: 4.129

Review 6.  Derailed estrogen signaling and breast cancer: an authentic couple.

Authors:  Bramanandam Manavathi; Oindrilla Dey; Vijay Narsihma Reddy Gajulapalli; Raghavendra Singh Bhatia; Suresh Bugide; Rakesh Kumar
Journal:  Endocr Rev       Date:  2012-09-04       Impact factor: 19.871

7.  The nuclear receptor transcriptional coregulator RIP140.

Authors:  Patrick Augereau; Eric Badia; Sophie Carascossa; Audrey Castet; Samuel Fritsch; Pierre-Olivier Harmand; Stéphan Jalaguier; Vincent Cavaillès
Journal:  Nucl Recept Signal       Date:  2006-10-30

8.  The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals.

Authors:  Jaya Nautiyal; Jennifer H Steel; Meritxell Rosell Mane; Olayiwola Oduwole; Ariel Poliandri; Xanthippi Alexi; Nicholas Wood; Matti Poutanen; Wilbert Zwart; John Stingl; Malcolm G Parker
Journal:  Development       Date:  2013-03       Impact factor: 6.868

9.  Suppressing NRIP1 inhibits growth of breast cancer cells in vitro and in vivo.

Authors:  Moammir H Aziz; Xundi Chen; Qi Zhang; Chad DeFrain; Jared Osland; Yizhou Luo; Xin Shi; Rong Yuan
Journal:  Oncotarget       Date:  2015-11-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.